Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group

Leukemia and Lymphoma

Volumn 49, Issue 6, 2008, Pages 1142-1154

  Trigg, Michael E ^a   Sather, Harland N ^b   Reaman, Gregory H ^c   Tubergen, David G ^d   Steinherz, Peter G ^e   Gaynon, Paul S ^f   Uckun, Fatih M ^g   Hammond, G Denman ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g PARKER HUGHES INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; Cancer; Children; Pediatric; Treatment outcome

Indexed keywords

ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PREVENTION; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOPHENOTYPING; INFANT; LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPROTECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SKULL IRRADIATION; STRATEGIC PLANNING; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHILD; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 46749141392     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802074593     Document Type: Article

References (46)

1. Miller, D. R., Leikin, S., Albo, V., Sather, H., Karon, M. and Hammond, D. (1983) Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from Children's Cancer Study Group. Cancer, 51, pp. 1041-1049.
2. Miller, D. R., Leikin, S., Albo, V., Vitale, L., Sather, H. Coccia, P. et al. (1980) Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group Report. Cancer Treatment Rep, 64, pp. 381-392.
3. Gaynon, P. S., Bleyer, W. A., Steinherz, P. G., Finklestein, J. Z., Littman, P. S. Miller, D. R. et al. (1988) Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features: A report of Children's Cancer Study Group Study CCG-193p. Am J Pediatr Hematol Oncol, 10, pp. 42-50.
4. Nachman, J., Sather, H. N., Cherlow, J. M., Sensel, M. G., Gaynon, P. S. Lukens, J. N. et al. (1998) Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group. J Clin Oncol, 16, pp. 920-930.
5. Nachman, J. B., Sather, H. N., Sensel, M. G., Trigg, M. E., Cherlow, J. M. Lukens, J. N. et al. (1998) Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med, 338, pp. 1663-1671.
6. Steinherz, P. G., Redner, A., Steinherz, L., Meyers, P., Tan, C. and Heller, G. (1993) Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer, 72, pp. 3120-3130.
7. Tubergen, D. G., Gilchrist, G. S., O'Brien, R. T., Coccia, P. F., Sather, H. N. Waskerwitz, M. J. et al. (1993) Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol, 11, pp. 527-537.
8. Uckun, F. M., Reaman, G., Steinherz, P. G., Arthur, D. C., Sather, H. Trigg, M. et al. (1996) Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Leuk Lymphoma, 24, pp. 57-70.
9. Abromowitch, M., Ochs, J., Pui, C. H., Kalwinsky, D., Rivera, G. K. Fairclough, D. et al. (1988) High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude total therapy study X. Med Pediatr Oncol, 16, pp. 297-303.
10. Bloomfield, C. D., Secker Walker, L M, Goldman, A. I., Van Den Berghe, H, de la Chapelle, A. Ruutu, T. et al. (1989) Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet, 40, pp. 171-185.
11. Clavell, L. A., Gelber, R. D., Cohen, H. J., Hitchcock-Bryan, S., Cassady, J. R. Tarbell, N. J. et al. (1986) Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med, 315, pp. 657-663.
12. Freeman, A. I., Boyett, J. M., Glicksman, A. S., Brecher, M. L., Leventhal, B. G. Sinks, L. F. et al. (1997) Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: A ten-year follow-up. Med Pediatr Oncol, 28, pp. 98-107.
13. Janka, G. E., Winkler, K., Juergens, H. and Goebel, U. (1987) Early intensification therapy in high-risk childhood acute lymphocytic leukemia: Lack of benefit from high-dose methotrexate. Haematol Blood Transfus, 30, pp. 456-460.
14. Mastrangelo, R., Poplack, D., Bleyer, A., Riccardi, R., Sather, H. and D'Angio, G. (1986) Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol, 14, pp. 191-194.
15. Pui, C. H., Frankel, L. S., Carroll, A. J., Raimondi, S. C., Shuster, J. J. Head, D. R. et al. (1991) Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): A collaborative study of 40 cases. Blood, 77, pp. 440-447.
16. Riehm, H., Feickert, H. J., Schrappe, M., Henze, G. and Schellong, G. (1987) Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transfus, 30, pp. 139-146.
17. Schorin, M. A., Blattner, S., Gelber, R. D., Tarbell, N. J., Donnelly, M. Dalton, V. et al. (1994) Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol, 12, pp. 740-747.
18. Smith, M., Arthur, D., Camitta, B., Carroll, A. J., Crist, W. Gaynon, P. et al. (1996) Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol, 14, pp. 18-24.
19. Gaynon, P. S., Steinherz, P. G., Bleyer, W. A., Ablin, A. R., Albo, V. C. Finklestein, J. Z. et al. (1988) Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Children's Cancer Study Group. Lancet, 2, pp. 921-924.
20. Gaynon, P. S., Steinherz, P. G., Bleyer, W. A., Ablin, A. R., Albo, V. C. Finklestein, J. Z. et al. (1993) Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol, 11, pp. 2234-2242.
21. Steinherz, P. G., Gaynon, P. S., Breneman, J. C., Cherlow, J. M., Grossman, N. J. Kersey, J. H. et al. (1996) Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Children's Cancer Group. J Clin Oncol, 14, pp. 389-398.
22. Steinherz, P. G., Gaynon, P. S., Breneman, J. C., Cherlow, J. M., Grossman, N. J. Kersey, J. H. et al. (1998) Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the Children's Cancer Group. Cancer, 82, pp. 600-612.
23. Tubergen, D. G., Gilchrist, G. S., O'Brien, R. T., Coccia, P. F., Sather, H. N. Waskerwitz, M. J. et al. (1993) Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Children's Cancer Group report. J Clin Oncol, 11, pp. 520-526.
24. Bleyer, W. A., Coccia, P. F., Sather, H. N., Level, C., Lukens, J. Niebrugge, D. J. et al. (1983) Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol, 1, pp. 317-325.
25. Lange, B. J., Blatt, J., Sather, H. N. and Meadows, A. T. (1996) Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Children's Cancer Group study. Med Pediatr Oncol, 27, pp. 15-20.
26. Steinherz, P. G., Gaynon, P. S., Miller, D. R., Reaman, G., Bleyer, A. Finklestein, J. et al. (1986) Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - a new intensive therapy protocol: A report from the Children's Cancer Study Group. J Clin Oncol, 4, pp. 744-752.
27. Anderson, J. R., Wilson, J. F., Jenkin, D. T., Meadows, A. T., Kersey, J. Chilcote, R. R. et al. (1983) Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med, 308, pp. 559-565.
28. Reaman, G. H., Sposto, R., Sensel, M. G., Lange, B. J., Feusner, J. H. Heerema, N. A. et al. (1999) Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol, 17, pp. 445-455.
29. Coccia, P., Bleyer, W., Siegel, S., Lukens, J. N., Gross, S. Miller, D. R. et al. (1983) Development and preliminary findings of Children's Cancer Study Group protocols (161, 162 and 163) for low-, average- and high-risk acute lymphoblastic leukemia in children. pp. 241-250. Elsevier Science Publishing Co, Inc, Amsterdam
30. Uckun, F. M., Muraguchi, A., Ledbetter, J. A., Kishimoto, T., O'Brien, R. T. Roloff, J. S. et al. (1989) Biphenotypic leukemic lymphocyte precursors in CD2 + CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood, 73, pp. 1000-1015.
31. Kaplan, E. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
32. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R. Howard, S. V. et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer, 35, pp. 1-39.
33. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, pp. 163-170.
34. Cox, D. R. (1972) Regression models and life tables. J R Stat Soc B, 34, pp. 187-220.
35. Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W-D henze, G. et al. (2000) Long-term results of four consecutive trials in childhood ALL performred by the ALL-BFM study group from 1981 to 1995. Leukemia, 14, pp. 2205-2222.
36. Gaynon, P. S., Trigg, M. E., Heerema, N. A., Sensel, M. G., Sather, H. N., Hammond, G. D. and Bleyer, W. A. (2000) Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1883-1995. Leukemia, 14, pp. 2223-2233.
37. Silverman, L. B., Declerck, L., Gelber, R. D., Kimball Dalton, V, Asselin, B. L. Barr, R. D. et al. (2000) Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia, 14, pp. 2247-2256.
38. Pui, C-H, Boyett, J. M., Rivera, G. K., Hancock, M. L., Sandlund, J. T. Ribeiro, R. C. et al. (2000) Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia, 14, pp. 2286-2294.
39. Eden, O. B., Harrison, G., Richards, S., Lilleyman, J. S., Bailey, C. C. Chessells, J. M. et al. (2000) Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Leukemia, 14, pp. 2307-2320.
40. Gaynon, P. S., Desai, A. A., Bostrom, B. C., Hutchinson, R. J., Lange, B. J. Nachman, J. B. et al. (1997) Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review. Cancer, 80, pp. 1717-1726.
41. Rivera, G. K., Pinkel, D., Simone, J. V., Hancock, M. L. and Crist, W. M. (1993) Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med, 329, pp. 1289-1295.
42. Chessells, J. M. (1983) Childhood acute lymphoblastic leukemia: The late effects of treatment. Br J Haematol, 63, pp. 369-378.
43. Gaynon, P. S., Steinherz, P. G., Reaman, G. H., Bleyer, W. A., Sather, H. and Hammond, G. D. (1987) Strategies for the treatment of children with acute lymphoblastic leukemia and unfavorable presenting features. Haematol Blood Transfus, 30, pp. 167-172.
44. Bostrom, B. C., Sensel, M. R., Sather, H. N., Gaynon, P. S., La, M. K. Johnston, K. et al. (2003) Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood, 101, pp. 3809-3817.
45. Schrappe, M., Reiter, A., Ludwig, W. D., Harbott, J., Zimmermann, M. Hiddemann, W. et al. (2000) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group. Blood, 95, pp. 3310-3322.
46. Camitta, B., Mahoney, D., Leventhal, B., Lauer, S. J., Shuster, J. J. Adair, S. et al. (1994) Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol, 12, pp. 1383-1389.